Related Experiment Videos
Early intervention for persons infected with human immunodeficiency virus
1Division of STD/HIV Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
Summary
Early intervention for human immunodeficiency virus (HIV) infection includes monitoring immune function and preventing transmission. Evidence supports many interventions, but efficacy for some immunizations and early antiretroviral therapy requires further study.
Area of Science:
- Infectious Diseases
- Immunology
- Public Health
Background:
- Early intervention is crucial for managing human immunodeficiency virus (HIV) infection.
- Management includes staging disease, initiating therapy, and preventing transmission.
- Current recommendations focus on evaluation and management strategies.
Purpose of the Study:
- To review the efficacy of current recommendations for early HIV infection management.
- To identify interventions with strong evidence of clinical benefit.
- To highlight areas where evidence is less certain.
Main Methods:
- Review of available data on current HIV management guidelines.
- Assessment of evidence supporting various diagnostic and therapeutic interventions.
- Evaluation of monitoring strategies, including CD4+ cell counts and viral titers.
Main Results:
- Strong evidence supports physical examination, CD4+ counts, tuberculin testing, anergy testing, Papanicolaou tests, STI screening, syphilis screening, antiretroviral therapy for symptomatic patients, and HIV transmission reduction counseling.
- Evidence for immunizations (influenza, S. pneumoniae, H. influenzae, HBV) and antiretroviral therapy for asymptomatic patients is less certain.
- Quantitative viral titers show promise for monitoring but require correlation with clinical outcomes.
Conclusions:
- Many current recommendations for early HIV management are supported by robust evidence.
- Further research is needed to confirm the efficacy of certain immunizations and early antiretroviral therapy.
- Monitoring viral titers may enhance disease and treatment assessment but needs validation against clinical endpoints.